Key points are not available for this paper at this time.
ABSTRACT Given the confluence of dysregulated inflammation, vasculopathy, and neuropathy, diabetic wounds pose a significant clinical challenge. Commercially available wound dressings often lack sufficient bioactivity, failing to meet clinical demands. Herein, we developed a PCL‐PLLA‐MgSiO 3 (PP‐MgSi) patch with promising therapeutic effects. The PP‐MgSi composite patch was manufactured via electrospinning and characterized by controllable degradation and local release of Mg 2+ and SiO 3 2 − . The patch showed favorable in vitro biocompatibility and bioactivity, notably increased angiogenesis, myelination, and neurite outgrowth. In type 2 diabetic mice, the PP‐MgSi patch exhibited MgSi dose‐dependent effects on enhancing diabetic wound healing by modulating the expression of TNF‐α, iNOS, and CD206 to balance inflammation, while boosting CD31 and β3‐tubulin levels to promote neurovascularization. With the significant suppression of pro‐inflammatory‐related TNF and IL‐17 pathways, while activating the peripheral nerve‐associated axon guidance pathway, blood vessel‐associated HIF‐1α and VEGF pathways, the PP‐MgSi patch ultimately achieved accelerated healing compared to the control group. Ultimately, the PP‐MgSi patch exhibited an accelerated repair rate, with comparable neovascularization and superior peripheral nerve regeneration capacity compared to three representative commercially available products. This proof‐of‐concept work presents a promising bioactive PP‐MgSi patch for future clinical diabetic wound management, particularly in terms of its neurovascular network recovery properties.
Xu et al. (Tue,) studied this question.